Effectiveness and safety of non-tumor necrosis factor inhibitor therapy for anti-human T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis

References

• de The G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses. 1993;9(5):381–6.
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y, et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr (1988). 1990;3(11):1096–101.
   PubMed Web of Science ®Google Scholar
• Quaresma JA, Yoshikawa GT, Koyama RV, Dias GA, Fujihara S, Fuzii HT. HTLV-1, immune response and autoimmunity. Viruses 2015;8(1):5.
   Web of Science ®Google Scholar
• Eguchi K, Origuchi T, Takashima H, Iwata K, Katamine S, Nagataki S. High seroprevalence of anti-HTLV-I antibody in rheumatoid arthritis. Arthritis Rheum. 1996;39(3):463–6.
   PubMed Web of Science ®Google Scholar
• Sakai M, Eguchi K, Terada K, Nakashima M, Yamashita I, Ida H, et al. Infection of human synovial cells by human T cell lymphotropic virus type I. Proliferation and granulocyte/macrophage colony-stimulating factor production by synovial cells. J Clin Invest. 1993;92(4):1957–66.
   PubMed Web of Science ®Google Scholar
• Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, for the Joint Study on Predisposing Factors of ATL Development investigators, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116(8):1211–9.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Fukui S, Umekita K, Miyamoto J, Umeda M, Nishino A, et al. Brief report: attenuated effectiveness of tumor necrosis factor inhibitors for anti-human T lymphotropic virus type I antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2018;70(7):1014–21.
   PubMed Web of Science ®Google Scholar
• D'Agostino MA, Wakefield RJ, Berner-Hammer H, Vittecoq O, Filippou G, Balint P, OMERACT-EULAR-Ultrasound Task Force, et al. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. Ann Rheum Dis. 2016;75(10):1763–9.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
   PubMed Web of Science ®Google Scholar
• van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum.1998;41(10):1845–50.
   PubMed Web of Science ®Google Scholar
• Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113(521):390–400.
   Web of Science ®Google Scholar
• Lumley T. Analysis of complex survey samples. J Stat Softw. 2004;9(1):1–19.
   Google Scholar
• Lumley T. Complex surveys: a guide to analysis using R. Hoboken, NJ: John Wiley and Sons; 2010.
   Google Scholar
• Lumley T. Survey: Analysis of complex survey samples. R package version 4.0 2020. Available from: https://cran.r-project.org/web/packages/survey/.
   Google Scholar
• Yoshida K, Bartel A. Create ‘Table 1' to Describe Baseline Characteristics with or without Propensity Score Weights. Available from: https://CRAN.R-project.org/package=tableone.
   Google Scholar
• R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria; 2020. Available from: https://www.R-project.org/.
   Google Scholar
• Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol. 2011;21(4):365–9.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, et al. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice? Clin Rheumatol. 2017;36(6):1215–20.
   PubMed Web of Science ®Google Scholar
• Fukui S, Nakamura H, Takahashi Y, Iwamoto N, Hasegawa H, Yanagihara K, et al. Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy. BMC Immunol. 2017;18(1):7.
   PubMedGoogle Scholar
• Nakamura H, Ueki Y, Saito S, Horai Y, Suzuki T, Naoe T, et al. Development of adult T-cell leukemia in a patient with rheumatoid arthritis treated with tocilizumab. Intern Med. 2013;52(17):1983–6.
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research. Clin Cancer Res. 2014;20(20):5217–25.
   PubMed Web of Science ®Google Scholar
• Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol. 2012;3:389.
   PubMed Web of Science ®Google Scholar
• Eguchi K, Iwanaga M, Terada K, Aramaki T, Tuji Y, Kurushima S, et al. Clinical features and human T-cell leukemia virus type-1 (HTLV-1) proviral load in HTLV-1-positive patients with rheumatoid arthritis: Baseline data in a single center cohort study. Mod Rheumatol. 2020;30(3):471–80.
   PubMed Web of Science ®Google Scholar